293FT is a highly suitable mammalian cell line for the in vitro enzymatic activity analysis of typical P450 proteins

Pharmazie

Volumn 70, Issue 1, 2015, Pages 33-37

  Dai, D P ^a   Geng, P W ^b,c   Cai, J ^b   Wang, S H ^b,c   Nic, J J ^d   Hu, J H ^d   Hu, G X ^b   Cai, J P ^a  

^a BEIJING HOSPITAL   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c LISHUI PEOPLE S HOSPITAL   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 VARIANT; DICLOFENAC; GREEN FLUORESCENT PROTEIN; MEPHENYTOIN; PROTEIN VARIANT; UNCLASSIFIED DRUG; DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COS 7 CELL LINE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMAL CELL; MAMMALIAN CELL LINE; NONHUMAN; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PLASMID; PROTEIN SYNTHESIS;

CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION; HEK293 CELLS; HUMANS; PHARMACEUTICAL PREPARATIONS; PLASMIDS; PROTEIN BIOSYNTHESIS; TRANSFECTION;

EID: 84927552904     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2015.4067     Document Type: Article

References (33)

1. Bansal S, Anandatheerthavarada HK, Prabu GK, Milne GL, Martin MV, Guengerich FP, Avadhani NG (2013) Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models. J Biol Chem 288: 12627-12644.
2. Cavallari LH, Jeong H, Bress A (2011) Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med 4: 123-136.
3. Crane AL, Klein K, Zanger UM, Olson JR (2012) Effect of CYP2B6∗6 and CYP2C19∗2 genotype on chlorpyrifos metabolism. Toxicology 293: 115-122.
4. Dai DP, Wang YH, Wang SH, Geng PW, Hu LM, Hu GX, Cai JP (2013) In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. Acta Pharmacol Sin 34: 1449-1456.
5. Dai DP, Xu RA, Hu LM, Wang SH, Geng PW, Yang JF, Yang LP, Qian JC, Wang ZS, Zhu GH, Zhang XH, Ge RS, Hu GX, Cai JP (2014) CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J 14: 85-92.
6. De Morais SM,Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598.
7. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72: 76-89.
8. Guo Y,Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H (2005a) Catalytic activities of human cytochrome P450 2C9∗1, 2C9∗3 and 2C9∗13. Xenobiotica 35: 853-861.
9. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H (2005b) Role of CYP2C9 and its variants (CYP2C9∗3 and CYP2C9∗13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33: 749-753.
10. Hanioka N, Tanaka-Kagawa T, Miyata Y, Matsushima E, Makino Y, Ohno A, Yoda R, Jinno H, Ando M (2003) Functional characterization of three human cytochrome p450 2E1 variants with amino acid substitutions. Xenobiotica 33: 575-586.
11. Herman D, Dolzan V, Ingelman-Sundberg M (2007) Characterization of the novel defective CYP2C9∗24 allele. Drug Metab Dispos 35: 831-834.
12. Hiratsuka M(2012) In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 27: 68-84.
13. Honda M, Muroi Y, Tamaki Y, Saigusa D, Suzuki N, Tomioka Y, Matsubara Y, Oda A, Hirasawa N, Hiratsuka M (2011) Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether. Drug Metab Dispos 39: 1860-1865.
14. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31: 827-832.
15. Hu LM, Dai DP, Hu GX, Yang JF, Xu RA, Yang LP, Qian JC, Ge RS, Cai JP (2012) Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population. Pharmacogenomics 13: 1571-1581.
16. Hua P, Liu LB, Liu JL, Wang M, Jiang HQ, Zeng K, Yang YQ, Yang SR (2013) Inhibition of apoptosis by knockdown of caspase-3 with siRNA in rat bone marrow mesenchymal stem cells. Exp Biol Med (Maywood) 238: 991-998.
17. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526.
18. Johansson I, Ingelman-Sundberg M (2011) Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci 120: 1-13.
19. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A (2002) Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos 30: 595-601.
20. Neunzig I,Widjaja M, Peters FT, Maurer HH, Hehn A, Bourgaud F, Bureik M (2013) Coexpression of CPR from various origins enhances biotransformation activity of human CYPs in S. pombe. Appl Biochem Biotechnol 170: 1751-1766.
21. Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, Hiratsuka M (2013). Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 14:107-114.
22. Qian JC, Xu XM, Hu GX, Dai DP, Xu RA, Hu LM, Li FH, Zhang XH, Yang JF, Cai JP (2013a) Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics 14: 1731-1743.
23. Qian W, Jin N, Shi J, Yin X, Jin X, Wang S, Cao M, Iqbal K, Gong CX, Liu F (2013b) Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression. J Alzheimers Dis 37: 529-538.
24. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4: 39-42.
25. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, Hiratsuka M (2008) Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 36: 2460-2467.
26. Sim SC, Ingelman-Sundberg M (2013). Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYPallele) Nomenclature Database. Methods Mol Biol 987: 251-259.
27. Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS (2012) Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 22: 590-597.
28. Takeda S, Ishii Y, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H (2005) Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450 s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull 28: 2026-2027.
29. Watanabe T, Sakuyama K, Sasaki T, Ishii Y, Ishikawa M, Hirasawa N, Hiratsuka M (2010) Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenet Genomics 20: 459-462.
30. Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M (2001) Characterization of the CYP2D6∗29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11: 417-427.
31. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinković D, Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424: 464-468.
32. Ye F, Zhong B, Dan G, Jiang F, Sai Y, Zhao J, Sun H, Zou Z (2013) Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct. Arch Med Sci 9: 561-568.
33. Zuo J, Xia D, Jia L, Guo T (2012) Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie 67: 639-644.